TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.

Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Akero gets FDA’s ok to conduct Phase IIb/III study of FGF21 analog efruxifermin in biopsy-confirmed non-alcoholic steatohepatitis patients. With NASH leadership up in the air, Akero, 89bio and other FGF analog sponsors jockey for top spot.

Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.

Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.

The rollercoaster ride continues for Novartis’s gene therapy Zolgensma, with the company committing to providing further clinical data on an intrathecal formulation for older spinal muscular atrophy patients.

A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.

Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.